Seeking Clues to Steris (STE) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

The upcoming report from Steris (STE) is expected to reveal quarterly earnings of $2.38 per share, indicating an increase of 11.2% compared to the year-ago period. Analysts forecast revenues of $1.43 billion, representing an increase of 7.4% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.Given this perspective, it's time to examine the average forecasts of specific Steris metrics that are routinely monitored and predicted by Wall Street analysts.Analysts' assessment points toward 'Revenues- Healthcare' reaching $1.01 billion. The estimate indicates a year-over-year change of +6.9%.The consensus among analysts is that 'Revenues- Healthcare Products- Service' will reach $374.76 million. The estimate suggests a change of +6.2% year over year.The consensus estimate for 'Revenues- Healthcare Products- Capital Equipment' stands at $268.96 million. The estimate indicates a change of +7.7% from the prior-year quarter.Analysts forecast 'Revenues- Healthcare Products- Consumables' to reach $357.50 million. The estimate indicates a year-over-year change of +4.6%.Analysts expect 'Revenues- Applied Sterilization Technologies (AST)' to come in at $281.02 million. The estimate indicates a change of +9.5% from the prior-year quarter.It is projected by analysts that the 'Revenues- Life Sciences' will reach $137.24 million. The estimate indicates a year-over-year change of +7.3%.The average prediction of analysts places 'Revenues- Service' at $701.59 million. The estimate suggests a change of +10.8% year over year.The collective assessment of analysts points to an estimated 'Revenues- Product' of $724.60 million. The estimate points to a change of +4.1% from the year-ago quarter.Analysts predict that the 'Revenues- Life Sciences- Service' will reach $36.79 million. The estimate indicates a year-over-year change of +12.1%.According to the collective judgment of analysts, 'Revenues- Life Sciences- Consumables' should come in at $71.75 million. The estimate indicates a year-over-year change of -0.5%.The combined assessment of analysts suggests that 'Revenues- Life Sciences- Capital Equipment' will likely reach $27.85 million. The estimate indicates a change of +21% from the prior-year quarter.Based on the collective assessment of analysts, 'Operating income / (loss)- Healthcare' should arrive at $239.46 million. The estimate is in contrast to the year-ago figure of $228.01 million. View all Key Company Metrics for Steris here>>> Shares of Steris have demonstrated returns of -1.4% over the past month compared to the Zacks S&P 500 composite's +2.1% change. With a Zacks Rank #4 (Sell), STE is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report STERIS plc (STE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks